ManaMed Reports Revolutionary Wearable Ultrasound Device Gains FDA Approval

Manamed, a pioneering Medical Technology development company, has been granted FDA approval on its latest orthopedic recovery device, ManaSport

What To Know

  • A complete therapy session takes just 20 minutes, and the product comes complete with everything you need to carry out therapy sessions, including ultrasound gel, a strap to hold the applicator in place, and a battery charger.
  • The ManaSport device, is a new ultrasound therapy device that provides pain relief and treatment for soft-tissue injuries and is popular among athletes and sports professionals.

FDA approval has now cleared the product for a range of indications for use, including:

Chronic pain relief.
Muscle spasms and joint contractures.
Relief from pain and joint contractures associated with adhesive capsulitis, bursitis with slight calcification, myositis, soft tissue injuries, and shortened tendons from past injuries and scar tissue.
Relief from pain and muscle spasms resulting from capsular tightness and capsular scarring.
Increasing localized blood flow.
Increasing the range of motion of contracted joints with heat and stretch techniques.

Portable and rechargeable, the device can now be prescribed by medical professionals and is intended for supervised use. It provides non-invasive pulsed ultrasound therapy at localized sites through ultrasound gel, with no discomfort to the patient. A complete therapy session takes just 20 minutes, and the product comes complete with everything you need to carry out therapy sessions, including ultrasound gel, a strap to hold the applicator in place, and a battery charger.

This compact medical device has an intuitive display with simple instructions for use. A built-in calendar helps users stay on top of treatments, while special safety features can lock the device to avoid unintended operation. Physicians and physiotherapists can manually move the applicator throughout the affected area, or use the included strap for a static, hands-free treatment.

Put simply, ManaSport provides a straightforward and effective solution for many medical and sports-related issues and conditions, without the need for surgery or opioids. With the new FDA approval, ManaSport is sure to become the go-to therapy for sports medicine doctors everywhere.

Trevor Theriot, President, and CEO commented, “ManaMed will continue to design, develop, and innovate the entire Med Tech space.  ManaSport demonstrates our commitment to invest in the future and expand our access to the entire continuum of care.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

XT-Thrive® Drug Master File (DMF) Accepted by the FDA | Reports X-Therma

X-Therma notes this DMF covers the Chemistry, Manufacturing and Controls (CMC) for this key chemistry innovation, which enables non-toxic cryopreservation for life-saving regenerative medicines.

Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte™ Image Guided Crossing and Re-Entry Catheter System

Simpson Interventions is committed to collaborating closely with the FDA and other stakeholders to advance the development and regulatory review of the Acolyte Image Guided Crossing and Re-Entry Catheter System. The company looks forward to bringing this revolutionary technology to clinicians, and patients in need.

Transforming Tricuspid Valve Care: FDA Gives Green Light to Abbott’s TriClip™

"The U.S. approval of TriClip is a significant advancement for people suffering from tricuspid regurgitation, a heart condition that negatively impacts their quality of life and puts them at grave risk of serious health issues," said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital and co-principal investigator of the TRILUMINATE™ Pivotal trial. "With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heart surgery that may not be feasible for individuals with TR who are generally older and sicker."

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

This make it one of the only wearable OTC anti-migraine device that is available without a prescription in the U.S.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version